ORCHID PHARMA Latest Share Price (ORCHPHARMA)
TODAY IN ONE LINE
ORCHPHARMA fell 1.3% on light volume, in line with Nifty's -0.3% move.
With a market cap of ₹5,122.63 Cr., it trades at a P/E of 478.67. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ORCHID PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 69.8% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.13x
- ●Promoter BuyingPromoters increased holdings by 69.84% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 3.3%
- ●Expensive ValuationTrading at a high P/E ratio of 240.7x
- ●Rising Receivables vs SalesReceivables grew 24.0% outpacing sales growth of 12.5%
Latest ORCHID PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
ORCHID PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ORCHID PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
ORCHID PHARMA trades at a P/E of 478.67× and P/B of 3.27×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ORCHID PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ORCHID PHARMA — derived from the latest tape, not yesterday's close.
ORCHID PHARMA last traded at ₹1,003.05 with an intraday range of ₹973.55–₹1,010 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1003.05| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1090.42 | +87.37 | +8.71% |
| R3 | 1053.97 | +50.92 | +5.08% |
| R2 | 1031.98 | +28.93 | +2.88% |
| R1 | 1017.52 | +14.47 | +1.44% |
| PIVOT | 995.53 | -7.52 | -0.75% |
| CURRENT | 1003.05 | — | — |
| S1 | 981.07 | -21.98 | -2.19% |
| S2 | 959.08 | -43.97 | -4.38% |
| S3 | 944.62 | -58.43 | -5.83% |
| S4 | 908.17 | -94.88 | -9.46% |
ORCHPHARMA is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹973.55–₹1005.5
Trading Inside opening range
ORCHID PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ORCHID PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
ORCHID PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹5,122.63 Cr. and reported EPS of ₹2.35.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 922 | 1,233 ▲ 33.7% |
| Sales Growth YoY %Derived | 12.52% | 33.72% |
| Other Income | 27 | 36 ▲ 32.6% |
| Total Income | 949 | 1,269 ▲ 33.7% |
| 544 | 844 ▲ 55.2% | |
| Gross ProfitDerived | 378 | 388 ▲ 2.8% |
| Gross Margin %Derived | 40.97% | 31.50% |
| 261 | 355 ▲ 36.2% | |
| EBITDA (Operating Profit)Derived | 117 | 34 ▼ 71.3% |
| OPM %Derived | 12.71% | 2.72% |
| 49 | 45 ▼ 8.5% | |
| Profit Before Tax (PBT) | 96 | 10 ▼ 89.1% |
| -0 | -0 ▲ 1.0% | |
| Effective Tax %Derived | -0.20% | -1.84% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 100 | 10 ▼ 90.0% |
| Net Profit (Owner's PAT)Derived | 100 | 10 ▼ 90.0% |
| Net Profit Margin %Derived | 10.81% | 0.81% |
| PAT Growth YoY %Derived | 8.13% | -90.01% |
| Earnings Per Share (EPS ₹) | 19.65 | 1.96 ▼ 90.0% |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% |
| Share of Profit from Associates/JVs | 4 | -1 ▼ 117.0% |
| Other Comprehensive Income (Net of Tax) | -1 | 1 ▲ 275.4% |
| Total Expenses (incl. D&A & Interest) | 854 | 1,259 ▲ 47.4% |
| Material Cost % of RevenueDerived | 63.50% | 62.57% |
| Employee Cost % of RevenueDerived | 9.37% | 9.54% |
| Other Cost % of RevenueDerived | 18.89% | 19.23% |
| Interest Coverage (x)Derived | 5.68x | -1.08x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 688 | 600 ▼ 12.8% | 508 ▼ 15.3% | 450 ▼ 11.4% | 560 ▲ 24.3% | 666 ▲ 19.0% | 819 ▲ 23.0% | 922 ▲ 12.5% | 1,233 ▲ 33.7% | |
| Sales Growth YoY %Derived | — | -12.77% | -15.32% | -11.41% | 24.33% | 19.00% | 23.05% | 12.52% | 33.72% | |
| Other Income | 20 | 17 ▼ 16.6% | 24 ▲ 44.7% | 15 ▼ 37.8% | 9 ▼ 40.9% | 19 ▲ 115.8% | 31 ▲ 58.8% | 27 ▼ 11.0% | 36 ▲ 32.6% | |
| Total Income | 708 | 617 ▼ 12.9% | 533 ▼ 13.7% | 465 ▼ 12.6% | 569 ▲ 22.2% | 685 ▲ 20.5% | 850 ▲ 24.1% | 949 ▲ 11.7% | 1,269 ▲ 33.7% | |
350 | 290 ▼ 17.3% | 243 ▼ 16.0% | 229 ▼ 6.1% | 314 ▲ 37.2% | 385 ▲ 22.7% | 484 ▲ 26.0% | 544 ▲ 12.3% | 844 ▲ 55.2% | ||
| Gross ProfitDerived | 338 | 310 ▼ 8.1% | 265 ▼ 14.7% | 222 ▼ 16.3% | 246 ▲ 11.0% | 281 ▲ 14.3% | 335 ▲ 19.1% | 378 ▲ 12.8% | 388 ▲ 2.8% | |
| Gross Margin %Derived | 49.09% | 51.72% | 52.11% | 49.23% | 43.96% | 42.24% | 40.87% | 40.97% | 31.50% | |
322 | 328 ▲ 2.0% | 290 ▼ 11.6% | 172 ▼ 40.8% | 196 ▲ 14.3% | 198 ▲ 0.6% | 224 ▲ 13.4% | 261 ▲ 16.2% | 355 ▲ 36.2% | ||
| EBITDA (Operating Profit)Derived | 16 | -18 ▼ 216.0% | -25 ▼ 39.9% | 50 ▲ 295.4% | 50 ▼ 0.3% | 84 ▲ 68.5% | 111 ▲ 32.4% | 117 ▲ 5.9% | 34 ▼ 71.3% | |
| OPM %Derived | 2.28% | -3.03% | -5.02% | 11.06% | 8.87% | 12.56% | 13.51% | 12.71% | 2.72% | |
435 | 331 ▼ 23.9% | 130 ▼ 60.7% | 160 ▲ 23.2% | 119 ▼ 25.7% | 126 ▲ 6.0% | 50 ▼ 60.7% | 49 ▼ 1.0% | 45 ▼ 8.5% | ||
| Profit Before Tax (PBT) | -399 | 69 ▲ 117.4% | -131 ▼ 288.8% | -95 ▲ 27.3% | -60 ▲ 36.6% | 55 ▲ 191.4% | 92 ▲ 66.4% | 96 ▲ 3.9% | 10 ▼ 89.1% | |
-46 | — ▲ 100.0% | — | — | — | — | -3 | -0 ▲ 93.8% | -0 ▲ 1.0% | ||
| Effective Tax %Derived | 11.58% | — | — | — | — | — | -3.39% | -0.20% | -1.84% | |
| Profit/Loss from Discontinued Ops | — | — | — | -21 | 58 ▲ 374.8% | -7 ▼ 111.6% | — ▲ 100.0% | — | — | |
| Total Profit for Period | -353 | 69 ▲ 119.7% | -131 ▼ 288.8% | -95 ▲ 27.3% | -2 ▲ 98.0% | 46 ▲ 2473.8% | 92 ▲ 99.0% | 100 ▲ 8.1% | 10 ▼ 90.0% | |
| Net Profit (Owner's PAT)Derived | -353 | 69 ▲ 119.7% | -131 ▼ 288.8% | -95 ▲ 27.3% | -2 ▲ 98.0% | 46 ▲ 2473.8% | 92 ▲ 99.0% | 100 ▲ 8.1% | 10 ▼ 90.0% | |
| Net Profit Margin %Derived | -51.29% | 11.57% | -25.80% | -21.16% | -0.35% | 6.96% | 11.25% | 10.81% | 0.81% | |
| PAT Growth YoY %Derived | — | 119.68% | -288.84% | 27.33% | 97.95% | 2,473.84% | 98.99% | 8.13% | -90.01% | |
| Earnings Per Share (EPS ₹) | -39.65 | 7.80 ▲ 119.7% | -32.11 ▼ 511.7% | -28.55 ▲ 11.1% | -0.48 ▲ 98.3% | 11.35 ▲ 2464.6% | 18.17 ▲ 60.1% | 19.65 ▲ 8.1% | 1.96 ▼ 90.0% | |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% | 4 ▼ 54.1% | 4 ▲ 0.0% | 4 ▲ 0.0% | 4 ▲ 0.0% | 5 ▲ 24.3% | 5 ▲ 0.0% | 5 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | — | — | -2 | -3 ▼ 34.6% | 4 ▲ 234.5% | -1 ▼ 117.0% | |
| Other Comprehensive Income (Net of Tax) | 1 | 1 ▲ 21.8% | -2 ▼ 323.7% | 1 ▲ 132.9% | 1 ▲ 114.1% | -0 ▼ 112.6% | -0 ▼ 88.6% | -1 ▼ 122.8% | 1 ▲ 275.4% | |
| Total Expenses (incl. D&A & Interest) | 1,107 | 548 ▼ 50.5% | 664 ▲ 21.2% | 561 ▼ 15.5% | 629 ▲ 12.2% | 630 ▲ 0.2% | 758 ▲ 20.3% | 854 ▲ 12.6% | 1,259 ▲ 47.4% | |
| Material Cost % of RevenueDerived | 49.64% | 43.81% | 46.36% | 54.57% | 60.87% | 60.98% | 64.48% | 63.50% | 62.57% | |
| Employee Cost % of RevenueDerived | 12.54% | 13.71% | 16.68% | 14.91% | 11.31% | 9.81% | 8.50% | 9.37% | 9.54% | |
| Other Cost % of RevenueDerived | 34.27% | 41.04% | 40.45% | 23.26% | 23.79% | 19.87% | 18.87% | 18.89% | 19.23% | |
| Interest Coverage (x)Derived | -0.39x | -494.49x | -36.41x | -1.15x | -1.17x | 0.89x | 4.73x | 5.68x | -1.08x |
ORCHID PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at ORCHID PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
ORCHID PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ORCHID PHARMA.
Our AI distills the core fundamental drivers supporting ORCHID PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ORCHID PHARMA's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 622 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
ORCHID PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ORCHID PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ORCHID PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ORCHID PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ORCHID PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ORCHID PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ORCHID PHARMA stood at 61.1% of traded volume, against a 20-day average of 53.9%.
ORCHID PHARMA announcements: results, concalls, ratings, M&A.
Filings ORCHID PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ORCHID PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 120 documents below.
Updates
Orchid Pharma Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for FY 2025-26'.
Change in Management
Orchid Pharma Limited has informed the Exchange about appointment of cost auditor and change in designation of a Director.
Outcome of Board Meeting
Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.
Analysts/Institutional Investor Meet/Con. Call Updates
Orchid Pharma Limited has informed the Exchange about Transcript
Analysts/Institutional Investor Meet/Con. Call Updates
Orchid Pharma Limited has informed the Exchange about Link of Recording
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
ORCHID PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ORCHID PHARMA has declared, sequenced by announce and record date.
ORCHID PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ORCHID PHARMA: business, sector, key facts.
What ORCHID PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ORCHID PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ORCHPHARMA, BSE: 524372.
Orchid Pharma Limited is an Indian pharmaceutical company specializing in the development, production, and marketing of a diverse range of pharmaceutical products. Their core offerings encompass active pharmaceutical ingredients (APIs), bulk drugs, finished dosage formulations (FDFs), and nutraceuticals. This broad portfolio allows them to cater to various sectors within the pharmaceutical industry, demonstrating a robust and diversified business model.
Within their API portfolio, Orchid Pharma focuses on key therapeutic areas. A significant portion of their business involves cephalosporins, both oral and injectable forms, used extensively in treating bacterial infections. They also manufacture veterinary products and non-antibiotic APIs, expanding their reach into different animal health and human health applications. This strategic diversification minimizes reliance on any single product or market segment.
Orchid Pharma boasts a multi-therapeutic presence across several key medical areas. These include anti-infectives (a significant area given their cephalosporin expertise), anti-inflammatory drugs, central nervous system medications, and cardiovascular drugs. The addition of nutraceuticals showcases a strategic move into the growing health and wellness market. Their product range further extends to other oral and sterile formulations, covering a wide spectrum of healthcare needs.
Beyond their manufacturing and marketing activities, Orchid Pharma offers specialized services in new drug discovery systems and pharmaceutical research and development. This positions them not only as a producer but also as a valuable partner for other pharmaceutical companies seeking innovative solutions and development expertise. Their international presence is also noteworthy, with exports to approximately 40 countries, indicating a significant global reach and market penetration.
Established in 1992 and currently a subsidiary of Dhanuka Laboratories Limited, Orchid Pharma (formerly Orchid Chemicals & Pharmaceuticals Limited) has a long history in the industry. Based in Narsinghpur, India, the company's integrated approach combining API manufacturing, formulation development, and global marketing contributes to its position as a significant player in the Indian and international pharmaceutical markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ORCHID PHARMA (ORCHPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ORCHID PHARMA (ORCHPHARMA)?
The current share price of ORCHID PHARMA (ORCHPHARMA) is ₹1,003.05. Today, the stock has declined by ₹13.05 (1.28%), trading in a range of ₹973.55 to ₹1,010.00. The stock opened at ₹1,005.50 with a trading volume of 68,916 shares.
02Is ORCHID PHARMA stock a good investment for long-term?
ORCHID PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹5,122.63 Cr., P/E ratio of 478.67, ROE of 3.3%, and ROCE of 3.77%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ORCHID PHARMA stock?
The 52-week high price of ORCHID PHARMA (ORCHPHARMA) is ₹1,133.00, while the 52-week low is ₹480.00. Currently trading at ₹1,003.05, the stock is 108.97% above its 52-week low and 11.47% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ORCHID PHARMA stock at the current price?
Whether to buy ORCHID PHARMA stock at ₹1,003.05 depends on multiple factors. The stock is currently trading with a P/E ratio of 478.67 and P/B ratio of 3.27. Today's performance shows a loss of 1.28%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ORCHID PHARMA and when is the next dividend?
ORCHID PHARMA offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹1,003.05, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹12.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ORCHID PHARMA?
ORCHID PHARMA's key financial metrics include: P/E Ratio: 478.67, P/B Ratio: 3.27, ROE: 3.3%, ROCE: 3.77%, Dividend Yield: 0%, EPS: ₹2.35, Book Value: ₹308.43, and Debt-to-Equity: 0.13. The company's market cap stands at ₹5,122.63 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ORCHID PHARMA stock performing today in the market?
ORCHID PHARMA stock opened at ₹1,005.50 and is currently trading at ₹1,003.05, showing a decline of ₹13.05 (1.28%). The intraday high is ₹1,010.00 and low is ₹973.55. The trading volume stands at 68,916 shares, indicating moderate market participation today.
08What is the P/E ratio of ORCHID PHARMA and what does it indicate?
ORCHID PHARMA has a Price-to-Earnings (P/E) ratio of 478.67, which means investors are willing to pay 478.67 for every ₹1 of earnings. With an EPS of ₹2.35, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ORCHID PHARMA (ORCHPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.